INNOVATE Corp. Files 8-K Report
Ticker: VATE · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1006837
| Field | Detail |
|---|---|
| Company | Innovate Corp. (VATE) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
INNOVATE Corp. (formerly HC2 Holdings) filed an 8-K on Jan 17, 2025, covering other events and financials.
AI Summary
On January 17, 2025, INNOVATE Corp. filed an 8-K report detailing other events and financial statements. The company, formerly known as HC2 Holdings, Inc., is incorporated in Delaware and headquartered in New York. This filing serves as a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides an update on significant events and financial information for INNOVATE Corp., which is crucial for investors to understand the company's current status and potential future developments.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report of events and financial statements, not indicating any immediate or significant risks.
Key Numbers
- 001-35210 — SEC File Number (Identifies the company's filing with the SEC.)
- 54-1708481 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- INNOVATE Corp. (company) — Registrant
- HC2 Holdings, Inc. (company) — Former company name
- January 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal business address city
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on 'Other Events' and 'Financial Statements and Exhibits' as of January 17, 2025.
What was INNOVATE Corp. previously known as?
INNOVATE Corp. was formerly known as HC2 Holdings, Inc., with previous name changes also noted from PTGi HOLDING, INC.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 17, 2025.
Where is INNOVATE Corp. incorporated and headquartered?
INNOVATE Corp. is incorporated in Delaware and has its principal business address in New York, NY.
What is the SIC code for INNOVATE Corp.?
The Standard Industrial Classification (SIC) code for INNOVATE Corp. is 3440, which corresponds to Fabricated Structural Metal Products.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-21 08:01:37
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VATE New York Stock Exchange
Filing Documents
- hchc-20250117.htm (8-K) — 34KB
- a202410258-kxexhibit991.htm (EX-99.1) — 28KB
- image_1a.jpg (GRAPHIC) — 4KB
- 0001006837-25-000002.txt ( ) — 247KB
- hchc-20250117.xsd (EX-101.SCH) — 3KB
- hchc-20250117_def.xml (EX-101.DEF) — 17KB
- hchc-20250117_lab.xml (EX-101.LAB) — 30KB
- hchc-20250117_pre.xml (EX-101.PRE) — 17KB
- hchc-20250117_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On January 17, 2025, INNOVATE Corp. issued a press release announcing that the U.S. Food and Drug Administration has approved the MediBeacon Transdermal GFR for the assessment of kidney function in patients with normal or impaired renal function. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 17 , 2025 , titled " MediBeacon Transdermal GFR Receives FDA Approval to Assess Kidney Function" 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 INNOVATE Corp. (Registrant) By: /s/ Michael J. Sena Name: Michael J. Sena Title: Chief Financial Officer